🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. Ex-vivo expanded allogeneic γδT cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab active

    1 trial

  2. Experimental Vaccine 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 1 mab completed

    1 trial

  3. Exposure to sporting events

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Heart Disease

    phase 1 other completed

    1 trial

  4. FMT capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypertension

    phase 1 mab active

    1 trial

  5. Fast Dual CAR-T Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Lymphoma

    phase 1 mab terminated

    1 trial

  6. Fospropofol disodium

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Drug Safety

    phase 1 small molecule completed

    1 trial

  7. GC012F Injection infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Inflammatory Myopathy (IIM)

    phase 1 small molecule active

    1 trial

  8. GPC3-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab on hold

    1 trial

  9. GV20-0251

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HCC - Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  10. Group A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 1 mab active

    1 trial

  11. Group A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  12. HBV mRNA vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cancer

    phase 1 mab active

    1 trial

  13. HN2301 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  14. HN2302 Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Disease

    phase 1 small molecule active

    1 trial

  15. HPV-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 1 mab active

    1 trial

  16. HRT, DHEA and herb

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Irregular Menses

    phase 1 small molecule completed

    1 trial

  17. Human Amniotic Epithelial Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  18. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  19. Human amniotic epithelial stem cells（hAESCs）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 1 mab terminated

    1 trial

  20. Human umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumoconiosis

    phase 1 mab active

    1 trial

  21. IASO104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 1 mab active

    1 trial

  22. IASO206 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  23. IASO206 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 1 small molecule active

    1 trial

  24. ICG-Cisplatin Nanoprobe (NIR-II NanoM)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cancer, Adult

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources